Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 4/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 13/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562111 | 0.88 | CCR6 (0.41) | CCR6CXCR2CNR1ATM | |
| SCHEMBL6562315 | 0.86 | CXCR2 (0.45) | CCR6CXCR2CNR1ATMPOLB | |
| SCHEMBL13205457 | 0.86 | ALDH1A1 (0.45) | CCR6CXCR2ATMPOLB | |
| SCHEMBL1563469 | 0.85 | CXCR2 (0.54) | CCR6CXCR2ATMPOLB | |
| SCHEMBL17293683 | 0.85 | TSHR (0.46) | CCR6CXCR2ATMPOLB | |
| SCHEMBL6564215 | 0.84 | CXCR2 (0.44) | CCR6CXCR2CNR1ATM | |
| SCHEMBL2767447 | 0.82 | CXCR2 (0.54) | CCR6CXCR2CNR1 | |
| SCHEMBL6563361 | 0.82 | POLB (0.44) | CNR1POLB | |
| SCHEMBL9978019 | 0.82 | SPR (0.47) | CCR6CXCR2ATM | |
| SCHEMBL17293877 | 0.81 | ATM (0.43) | CCR6CXCR2CNR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161232-B1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-6500863-B1 | INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2002-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | CXCL8, CCR8, IL18 | CCR6 32/4885CXCR2 26/4885CNR1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.